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ABSTRACT: Background. There are variations in the proportions of
head and neck cancers caused by the human papillomavirus (HPV)
between countries and regions. It is unclear if these are true variations
or due to different study designs and assays.
Methods. We tested formalin-fixed paraffin-embedded diagnostic biopsies
for p16 immunohistochemistry and HPV-DNA (by polymerase chain reac-
tion [PCR] and in situ hybridization [ISH]) using validated protocols on
samples from 801 patients with head and neck cancer recruited prospec-
tively between 2006 and 2011 in 4 randomized controlled trials (RCTs).
Results. Twenty-one percent of patients (170 of 801) showed both HPV-
DNA and p16-positivity, detected almost exclusively in oropharyngeal
cancer (55%; 15 of 302); and only 1% of the patients (5 of 499) with
nonoropharyngeal cancer were HPV positive. HPV-positive oropharyngeal
cancer differed between Western and Eastern Europe (37%, 155 of 422
vs 6%, 8 of 144; p < .0001) and between Western Europe and Asia
(37% vs 2%; 4 of 217; p < .0001). Other independent determinants of
HPV positivity were tumor site and smoking.
Conclusion. This is the first study to establish geographic variability as an
independent risk factor in HPV-positive oropharyngeal cancer prevalence,
with higher prevalence in Western Europe.VC 2016 The Authors Head & Neck
Published by Wiley Periodicals, Inc. Head Neck 38: E1863–E1869, 2016
KEY WORDS: oropharynx, head and neck cancer, squamous cell car-
cinoma, human papillomavirus, prevalence
INTRODUCTION
The proportion of head and neck cancers caused by the
human papillomavirus (HPV) seems to have increased
considerably over the past decade in several countries.1
However, there seems to be wide variations in the
reported rates of both HPV-positive oropharyngeal carci-
noma and nonoropharyngeal cancer among countries and
regions.1,2 There are also little recent data available for
Eastern Europe, Asia, or Africa.
It has become important to ascertain the regional differ-
ences in HPV-positive head and neck cancer to under-
stand the current trends and relative burden of HPV-
positive and HPV-negative head and neck cancer. This
will enable local clinicians and health commissioners to
plan for the provision of health care, rehabilitative, and
social support services for patients who are HPV-positive
who enjoy higher survival rates but have to deal with the
considerable sequelae of their intensive treatment.3 It may
also aid the assessment of the potential need for preventa-
tive public health measures; for example, the prophylactic
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vaccination of prepubescent boys, especially in regions
with high HPV prevalence.4,5 In addition, large phase III
studies in head and neck cancer need to be global to
facilitate timely recruitment and relevance across all
licensing jurisdictions. For this, the relative distributions
of HPV-positive and HPV-negative head and neck cancer
in these areas must be known.
The variations in reported regional prevalence rates
may be a reflection of regional differences in the profiles
of established risk factors, such as primary site, smoking,
or sexual habits,6 or as yet unknown factors. However,
there remains concern that a significant part of the vari-
ability between geographic regions and between primary
tumor sites may be due to study design biases, especially
the use of different HPV detection techniques with little
or no quality assurance,2,7 the inclusion of retrospective
cohorts recruited at different time periods,1,2,8 and mis-
classification of primary tumor sites.
In this study, our purposes were to overcome these
potential deficiencies, to provide a recent and more accu-
rate representation of the proportion of HPV-positive
head and neck cancer in different geographic regions, and
to assess the role of region as a risk factor for HPV-
positive head and neck cancer. We compared the propor-
tion of patients with HPV-positive head and neck cancers
and analyzed possible risk factors in a multinational
cohort of patients with head and neck cancer who were
all recruited prospectively in randomized controlled trials
(RCTs), within a recent time frame. All samples were
assessed for high-risk HPV-DNA using the same vali-
dated protocols in 2 quality-assured laboratories.
PATIENTS AND METHODS
Patients
We examined formalin-fixed paraffin-embedded diag-
nostic biopsies from a total of 1049 patients with head
and neck cancer who gave informed consent and were
recruited to 4 multicenter RCTs: PET NECK trial (187
subjects), GSK EGF104334 (107 subjects), GSK
EGF105884 (67 subjects), and GSK EGF102988 (688
subjects). Most subjects included in our study were
recruited between 2007 and 2010.
Ethical approval
Ethical approval for PET NECK trial (reference: 07/
Q1604/35) was granted by the Oxfordshire Research
Ethics Committee, May 2007. GSK EGF Ethical approval
(reference: 06/MRE12/82) was granted by the Thames
Valley Research Ethics Committee, March 2007.
The procedures followed were in accordance with the
ethical standards of the committees on human experimen-
tation and in accord with the Helsinki Declaration of
1975, as revised in 1983.
Tissue samples, human papillomavirus, and p16 testing
methods
Analysis was undertaken on tissue sections (4 lm) or
on tissue microarrays (TMAs) with up to four 0.6-mm
diameter cores from each case. We took 10-lm thick tis-
sue curls from available blocks for DNA extraction and
downstream polymerase chain reaction (PCR) analysis.
All samples were analyzed for p16 expression by immu-
nohistochemistry using a proprietary kit (CINtec Histol-
ogy; MTM Laboratories AG, Germany) on a Benchmark
Autostainer (Ventana Medical Systems, Sunnyvale, CA).
Two pathologists (H.W. and M.R.) scored the test results
independently, after undergoing calibration. Samples were
assessed for high-risk HPV-DNA using a protocol based
on that described and validated by Smeets et al.9 Samples
were assessed by HPV in situ hybridization (ISH), using
proprietary reagents (Inform HPV III Family 16 Probe
(B); Ventana) on a Benchmark Autostainer (Ventana).
For cases that were found to be p16-positive/HPV-nega-
tive by ISH using TMAs, whole tissue sections were
tested to reduce misclassification as a consequence of
possible sampling limitations inherent to TMA analysis.
If the case remained p16-positive/HPV-negative by ISH
on the whole tissue section, the case was then examined
by consensus PCR-enzyme immunoassay using a cocktail
of probes for 14 high-risk HPV types and separately with
a cocktail of probes for 6 low-risk types to control for the
suboptimal sensitivity of HPV-ISH compared to target
amplification techniques.9 This latter protocol has been
previously validated by our group and proven to have the
same accuracy as using p16 and HPV-PCR.10
For all samples in this study, cases that showed evi-
dence of HPV-DNA (either by ISH or consensus PCR)
and showed high p16 expression (HPV-positive/p16-posi-
tive) were defined as “harboring biologically relevant
oncogenic HPV infection.”9
Statistical analysis
All subjects who were enrolled into the studies but who
had not yet provided tumor tissue for biomarker testing
were included in a summary of baseline and disease char-
acteristics, but excluded from all other analyses. Subjects
who had provided tumor tissue that was inadequate for
testing were not included in the patient characteristics
summaries. The latter are based on the subset of subjects
who had valid results for both HPV and p16.
Subjects with at least one positive result for HPV and
one positive result for p16 for any of the cores and sec-
tions were considered to be positive overall for that bio-
marker. If the patient had no positive cores or sections,
then they were considered negative, otherwise their result
was treated as unknown, and they were not included in
the analysis. Subjects who tested negative for p16 and
who had an inconclusive result for HPV were considered
as HPV-negative overall.
The analysis includes only subjects with valid results
for both biomarkers (HPV-DNA and p16). The demo-
graphic and baseline disease characteristics, including
age, sex, primary tumor type, disease stage, smoking sta-
tus, and geographic region, were summarized for subjects
who had valid results for biomarkers, as well as those
who did not provide tumor tissue for testing or who had
insufficient tissue. The frequency and proportion of sub-
jects testing HPV-positive, p16-positive, and those with
combined positivity (HPV-DNA-positive and p16-posi-
tive) were also reported by these characteristics. Where
possible, odds ratios for combined positivity (HPV-DNA-
positive and p16-positive) were calculated for each
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characteristic, with suitable dichotomization where neces-
sary. A logistic regression analysis was used to model the
probability of testing positive for both HPV-DNA and
p16, adjusting for the risk factors listed above. Combined
test results were grouped into 4 categories: (1) HPV-posi-
tive/p16-positive; (2) HPV-positive/p16-negative; (3)
HPV-negative/p16-positive; and (4) p16-negative/HPV-
negative, and summarized for patients with oropharyngeal
cancer and nonoropharyngeal cancer tumors, as well as
by geographic region.
RESULTS
Patient characteristics
A total of 1049 patients submitted samples, constituting
81% of total subjects recruited in all 4 studies at the time
of the analysis. Eight hundred one patients had valid
results for both biomarkers. The primary tumors included
were squamous cell carcinomas originating from the oral
cavity in 241 patients (30%), the oropharynx in 302
patients (38%), the larynx in 159 patients (20%), and the
hypopharynx in 99 patients (12%). Compared to those
who were included in the analysis, the cases that were
not included had very similar baseline characteristics (see
Table 1).
Overall human papillomavirus-DNA and p16 incidence
Of the 801 patients who had valid results for both p16
and HPV-DNA, 193 (24%) showed HPV-DNA (by ISH
or PCR), 218 (27%) tested positive for p16, and 170
(21%) showed both HPV-DNA and p16-positivity
(Supplementary Table S1, online only).
Human papillomavirus prevalence by tumor site
There was a large difference in the distribution of HPV
and p16-positivity between tumor sites. Biologically rele-
vant, oncogenic high-risk HPV infection (HPV-DNA-pos-
itive/p16-positive) was detected almost exclusively in
oropharyngeal cancer (55%; 165 of 302 of oropharyngeal
cases), whereas 1% (5 of 499) of nonoropharyngeal head
and neck cancers were positive (Table 2 and Supplemen-
tary Table S1, online only).
Prevalence by geographic location
The prevalence of HPV-positivity in all cases of head
and neck cancer was significantly lower in subjects from
Asia (2%; 4 of 217) and Eastern Europe (6%; 8 of 144)
compared to Western Europe (37%; 155 of 422; p <
.0001 for both comparisons; Table 2).
Prevalence of biologically relevant oncogenic HPV
(HPV-DNA-positive and p16-positive) in oropharyngeal
cancer also differed significantly by geographic location:
63% of the patients (152 of 242) in Western Europe,
compared to 24% (8 of 33) in Eastern Europe (p <
.0001) and 9% (2 of 23) in Asia (p 5 .0001; Table 2).
For nonoropharyngeal head and neck cancer sites, HPV
prevalence was very low (1%), and did not differ by
region.
There were insufficient evaluable samples from North
and South America to accurately comment on their inci-
dence rates. There were also insufficient numbers to com-
pare incidence rates of individual countries.
Risk factors for human papillomavirus–positive
head and neck cancer
Factors significantly associated with HPV-positive head
and neck cancer, identified through univariate analysis,
were primary site, stage of disease, smoking status, and
geographic region. The overall odds of having HPV-
positive head and neck cancer in this 801 patient cohort
was significantly lower in subjects with oral (odds ratio
[OR] 5 0.0105; 95% confidence interval [CI] 5
0.00320.033; p < .0001), and laryngeal cancers (OR 5
0.0106; 95% CI 5 0.003–0.044; p < .0001] compared to
those with oropharyngeal cancer. The odds of having
HPV-positive cancer were also significantly lower for
current smokers relative to nonsmokers (OR 5 0.43; 95%
CI 5 0.26–0.73; p 5 .002) and for former smokers rela-
tive to nonsmokers (OR 5 0.59; 95% CI 5 0.39–0.89; p
5 .011). Subjects with stage IV disease were more likely
to have HPV-positive cancer (OR 5 15.1; 95% CI 5
2.1–110.4; p 5 .0115) compared to those with stage II
disease. Importantly, subjects from Western Europe had a
significantly higher risk of being HPV-positive compared
to those from Eastern Europe (OR 5 9.9; 95% CI 5 4.7–
20.7; p < .0001; see Figure 1). There was a trend toward
a lower risk of HPV-positivity in subjects from Asia (OR
5 0.32; 95% CI 5 0.09–1.1; p 5 .067) compared to
Eastern Europe, but this was not statistically significant.
There was no association with age or sex (p 5 .13 and
p 5 .32, respectively; Table 2).
TABLE 1. Summary of demography and disease characteristics.
Variables
Subjects not tested
for biomarkers
(n 5 248)
Subjects tested
for biomarkers
(n5 801)
Age, y
Mean 55.8 54.3
SD 9.90 8.65
Median 56.0 55.0
Minimum 28 24
Maximum 80 81
Sex
Female 45 (18%) 135 (17%)
Male 203 (82%) 666 (83%)
Primary tumor type
Oral cavity 84 (34%) 241 (30%)
Oropharynx 80 (32%) 302 (38%)
Hypopharynx 36 (15%) 99 (12%)
Larynx 48 (19%) 159 (20%)
Stage
II 5 (2%) 46 (6%)
III 47 (19%) 106 (13%)
IVa 179 (72%) 645 (81%)
IVb 17 (7%) 4 (<1%)
Geographic region
Eastern Europe 15 (6%) 144 (18%)
Western Europe 143 (58%) 422 (53%)
Asia 71 (29%) 217 (27%)
South America 13 (5%) 14 (2%)
North America 6 (2%) 4 (<1%)
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Considering only the 302 patients with oropharyngeal
cancer, the odds of combined HPV-DNA and p16-
positivity were again significantly lower for current smok-
ers relative to nonsmokers (OR 5 0.14; 95% CI 5 0.07–
0.31; p < .0001), for former smokers relative to non-
smokers (OR 5 0.36; 95% CI 5 0.18–0.71; p 5 .0035)
and significantly higher for subjects from Western Europe
(OR 5 5.28; 95% CI 5 2.28–12.20; p < .0001)
TABLE 2. Human papillomavirus-DNA and p16 incidence by age, sex, primary tumor type, smoking status, tumor stage, and geographic region.
HPV-DNA-positive, no.
of patients (%)
p16-positive, no.
of patients (%)
HPV-DNA-positive and
p16-positive, no.
of patients (%)
OR for HPV-positive
(HPV-DNA-positive and
p16-positive)*
Age category
50 y 45/236 (19) 52/236 (22) 42/236 (18) 0.74 (0.5, 1.09)
>50 y 148/565 (26) 166/565 (29) 128/565 (23) Reference
Sex
Male 156/666 (23) 173/666 (26) 137/666 (21) Reference
Female 37/135 (27) 45/135 (33) 33/135 (24) 1.25 (0.81, 1.93)
Primary tumor site
Oropharynx 173/302 (57) 186/302 (62) 165/302 (55) Reference
Oral cavity 4/241 (2) 13/241 (5) 3/241 (1) 0.0105 (0.0033, 0.0334)
Larynx 10/159 (6) 13/159 (8) 2/159 (1) 0.0106 (0.0026, 0.0435)
Hypopharynx 6/99 (6) 6/99 (6) 0/99
Smoking status
Never smoked 55/166 (33) 59/166 (36) 50/166 (30) Reference
Current smoker 37/178 (21) 39/178 (22) 28/178 (16) 0.43 (0.26, 0.73)
Former smoker 96/434 (22) 112/434 (26) 88/434 (20) 0.59 (0.39, 0.89)
Missing† 5/23 (22) 8/23 (35) 4/23 (17)
Stage
II 1/46 (2) 2/46 (4) 1/46 (2) Reference
III 10/106 (9) 15/106 (14) 6/106 (6) 2.7 (0.3, 23.1)
IV(a 1 b) 182/649 (28) 201/649 (31) 163/649 (25) 15.1 (2.1, 110.4)
Region, all cases
Eastern Europe 13/144 (9) 20/144 (14) 8/144 (6) Reference
Western Europe 166/422 (39) 176/422 (42) 155/422 (37) 9.87 (4.71, 20.69)
Asia 10/217 (5) 18/217 (8) 4/217 (2) 0.32 (0.09, 1.08)
South America 3/14 (21) 3/14 (21) 2/14 Too few cases to analyze
North America 1/4 (25) 1/4 (25) 1/4 Too few cases to analyze
Region, oropharyngeal cancer only
Eastern Europe 9/33 (27) 13/33 (39) 8/33 (24) Reference
Western Europe 159/242 (66) 166/242 (69) 152/242 (63) 5.28 (2.28, 12.20)
Asia 2/23 (9) 4/23 (17) 2/23 (9) 0.30 (0.06, 1.56)
South America 2/2 2/2 2/2 Too few cases to analyze
North America 1/2 1/2 1/2 Too few cases to analyze
Abbreviations: HPV, human papillomavirus; OR, odds ratio.
Note: The denominators are the numbers of subjects tested for both biomarkers.
* HPV DNA positive means position on HPV DNA in-situ hybridisation or HPV DNA PCR.
† Smoking status was not collected in study EGF104334.
FIGURE 1. Forest plots of pre-
dictors of human papillomavirus
(HPV) positivity for all subjects.
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compared to those from Eastern Europe (see Figure 2).
Again, there was a trend toward a lower likelihood of
HPV-positivity in oropharyngeal cancer subjects from
Asia (OR 5 0.3; 95% CI 5 0.06–1.56; p 5 .1511) com-
pared to Eastern Europe, but this did not reach statistical
significance. The odds for HPV-positive oropharyngeal
cancer were not significantly associated with age (OR for
those aged 50 years vs those aged >50 years 5 1.35;
95% CI 5 0.78–2.33; p 5 .29), or sex (OR for women
relative to men 5 1.38; 95% CI 5 0.8–2.5; p 5 .29), or
disease stage (OR for stage II vs other 5 0.16; 95% CI
5 0.02–1.39; p 5 .097 see Figure 2).
Multivariate analysis using a logistic regression model
was performed, first with inclusion of all potential risk
factors (age, sex, primary site, clinical stage, smoking sta-
tus, and geographic region), and second using stepwise
selection. Only primary site, smoking status, and geo-
graphic region were found to have a significant influence
on the probability of biologically relevant oncogenic HPV
infection (HPV-DNA and p16-positivity) in head and
neck cancer (Table 3 and Supplementary Table S2, online
only).
When examining risk factors for oropharyngeal cancer
alone, multivariate analysis revealed only smoking status
and geographic region to be significantly associated with
combined HPV-positivity and p16-positivity (Supplemen-
tary Table S3, online only). This was the same whether
the factors were introduced together or in a stepwise fash-
ion. There was no statistically significant interaction
between the risk factors (p 5 .69).
FIGURE 2. Forest plots of pre-
dictors of human papillomavirus
(HPV) positivity for patients with
oropharyngeal cancer only.
TABLE 3. Multivariate analyses of association of human papillomavirus positivity for all subjects using a model without selection.
Risk factor Coefficient, b (SE) p value
OR for combined HPV/
p16 positivity (95% CI)
Intercept 20.827 (1.583) .60 –
Smoking status
Never smoked, reference – – 1
Current 22.02 (0.43) < .0001 0.133 (0.06–0.31)
Former 21.39 (0.38) .0003 0.250 (0.12–0.53)
Sex
Male, reference group – – 1
Female 20.07 (0.34) .83 0.93 (0.475–1.818)
Region
Eastern Europe, reference – – 1
Asia 20.71 (0.77) .36 0.49 (0.11–2.23)
Western Europe 1.91 (0.46) < .0001 6.74 (2.72–16.72)
Tumor site
Oropharyngeal, reference – – 1
Nonoropharyngeal 24.38 (0.48) < .0001 0.013 (0.005–0.03)
Disease stage
II, reference group – – 1
III/IV 1.55 (1.33) .25 4.70 (0.35–63.9)
Age, y 20.01 (0.02) .45 0.99 (0.96–1.02)
Abbreviations: OR, odds ratio; HPV, human papillomavirus; 95% CI, 95% confidence interval.
The model using a stepwise logistic regression model is included as Supplementary Table S2, online only.
Age, sex, primary site, stage, smoking status, and region were introduced into the model.
All subjects, considering sex, disease stage, age, region (Eastern/Western Europe and Asia), tumor site, and smoking status without selection. Similar findings were observed when analyses were
repeated for oropharyngeal cancer subjects only (Supplementary Table S3, online only).
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DISCUSSION
This study demonstrated large, significant differences in
the proportion of HPV-positive oropharyngeal cancer
among Western Europe, Eastern Europe, and Asia, with
HPV-associated head and neck cancer being predomi-
nantly a disease of the oropharynx in Western Europe.
Geographic location seems to have a strong association
with HPV-positivity in oropharyngeal cancer, regardless
of smoking status, which is a well-established risk factor.
To the best of our knowledge, this is the first time that a
study firmly has established geographic variability in the
prevalence of HPV-positive oropharyngeal cancer. The
study highlights the need for ascertainment of local rates
before deciding on local health policies and strategies
related to oropharyngeal cancer. The results also demon-
strate the very low, relative prevalences of HPV in nonor-
opharyngeal cancer tumors, and emphasize that, despite
the current interest in HPV-related disease, the prevalence
of HPV-negative head and neck cancer in many countries
remains considerably higher than that of HPV-positive
disease.
By collating one of the largest cohorts ever collected,
using prospective multinational trials, and analyzing them
using the same assay and methodology, this study has
been able to overcome some of the main limitations of
previous studies. After accounting for tumor site and
smoking status, geographic region has a significant influ-
ence on the probability of testing positive for HPV. The
reasons for these geographic variations remain specula-
tive. A likely factor may be related to differences in the
prevalence rates of oral HPV infection.10 and the underly-
ing various sexual practices, particularly oral sex and
multiple sexual partners, which have been shown to be
risk factors for oral HPV infection and HPV-positive oro-
pharyngeal cancer6,11–13 It would be of interest to collect
sexual history in future trials. Other factors that could
explain these regional factors may be related to biological
and genetic differences in the population studied. This
holds true for other cancers; for example, in cervical
cancer (also caused by HPV), genetic differences may
determine susceptibility to HPV infection,14 and/or trans-
formation and progression of premalignant lesions to can-
cer.15 Importantly, however, because of our study design,
methodological and assay variations can be eliminated as
the potential main explanation for the wide geographic
differences in HPV-positivity rates.
Some hypothesize that smoking may protect against the
development of HPV-positive oropharyngeal cancer.16 As
smoking status is significantly associated with HPV-
positive oropharyngeal cancer rates (Tables 2 and 3), one
important potential explanation for regional variability in
HPV-positive oropharyngeal cancer rates may be differen-
ces in smoking behavior. Western European smoking
rates are thought to have decreased in recent years. An
association with smoking behavior could suggest that, as
smoking rates decrease in Eastern Europe and Asia,
HPV-positive oropharyngeal cancer rates may increase to
the levels of Western Europe. However, our study shows
that region continues to be an independent risk factor,
even after adjustment for smoking in the multivariate
analysis. Furthermore, analysis of reported national smok-
ing rates shows that although Eastern Europe has the
highest reported national cigarette consumption, China
has similar rates and India has much lower reported
national cigarette consumption compared to Western
Europe.17
This study had some limitations. Only 76% of eligible
subjects had evaluable samples. Although this is high
when compared to similar studies, it may have still intro-
duced bias to our results. The subjects included had been
recruited within trials with eligibility criteria, including
having treatment for curative intent. This introduces the
possibility of bias compared to population-based esti-
mates, which may also include subjects with very early
disease or those undergoing palliative treatment, who are
more likely to have HPV-negative oropharyngeal can-
cer.18 However, because the eligibility criteria were
applied consistently across all the recruiting countries, the
relative proportions of HPV-positivity and, hence, ORs
between regions are unlikely to change significantly.
Finally, there were lower numbers of cases included from
Eastern Europe and Asia compared to Western Europe.
There were also insufficient samples from the different
countries to allow definitive comparisons between coun-
tries of the same geographic region.
Our study also enabled the quantification of the relative
prevalence of HPV in nonoropharyngeal head and neck
cancer compared to oropharyngeal cancer, reports of which
have varied widely in the literature.1 The prevalence rate
of HPV in nonoropharyngeal head and neck cancer in our
study was much lower than that reported in previous, usu-
ally small retrospective studies.2 Our results seem to be
consistent with the low levels of HPV prevalence in nonor-
opharyngeal head and neck cancer reported by the larger
studies (eg, 1.6% by Scapoli et al).19
Our findings have implications for the planning of
future clinical trials. It is clear that HPV-positive and
HPV-negative head and neck cancers have different char-
acteristics and survival rates, and are thus different dis-
ease entities.20 As such, the need for collaboration of
national collaborative groups will become even more
important because of the fragmentation and stratification
of patient populations. By enabling more precise esti-
mates of regional prevalence of HPV-positivity, the data
in this study will help improve the accuracy of designing
and planning global trials in HPV-positive and HPV-
negative head and neck cancer.
The findings of this study also have significant implica-
tions for local health care policies. In regions where
HPV-positive disease is prevalent, it will be necessary to
consider and plan for the long-term support and survivor-
ship needs of these younger subjects, who are much more
likely to survive their cancer, but who will also have to
deal with the long-term effects on them and their families
of their disease and treatment.
Over three fourths of the subjects recruited in our study
had HPV-negative head and neck cancer (Table 2).
Although there is a lot of interest currently in HPV-
positive head and neck cancer, there is still a considerably
higher burden of HPV-negative head and neck cancer
globally. These subjects have a much worse prognosis
than their HPV-positive counterparts. More effective
treatment regimens are much needed to improve out-
comes of treatment for this large patient group.
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Finally, the significant differences in the prevalence
of HPV-positive head and neck cancer have implications
for preventative public health measures, especially in
resource-limited settings. The cost-effectiveness of the
HPV vaccination for prepubescent boys is highly depend-
ent on the prevalence of the disease, among other factors.
In areas of low HPV prevalence, especially in countries
with low health care expenditure, resource and efforts
may be best directed toward smoking cessation policies.
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